TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22068813
Drug: Balanced diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced diet (55 En% carbohydrates, 30 En% fat, 15 En% proteins) and exercise therapy once a week
Study: 22068813
Drug: Balanced diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced diet and exercise therapy
Study: 22069451
Drug: Isoniazid preventive
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid preventive therapy (IPT) for children ≤5 years old, duration of 6 months.
Study: 22071596
Drug: Afatinib 50
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Afatinib 50 mg/day
Study: 22071596
Drug: Afatinib 20-50
Normalized name: afatinib 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib 20-50 mg/day
Study: 22074178
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g PinnoThin TAG
Study: 22074178
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g PinnoThin TAG
Study: 22074813
Drug: Stimulant +
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant + Parent Training
Study: 22074813
Drug: Stimulant +
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant + Antipsychotic (Risperidone) + Parent Training
Study: 22077194
Drug: Preoperative intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative intravenous antibiotics
Study: 22077194
Drug: Postoperative systemic
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative systemic antibiotic therapy (68.7% of patients)
Study: 22077194
Drug: Povidone-iodine for
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone-iodine for topical antisepsis (used by sites with infection rates >5%)
Study: 22078932
Drug: Linifanib 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linifanib 0.25 mg/kg/day
Study: 22079051
Drug: Single Shot
Normalized name: ACL7 SINGLE SHOT EPIDURAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Shot 3D-CRT Partial Breast Irradiation (SSPBI) with a dose of 21 Gy
Study: 22079876
Drug: Intramuscular infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular infusion of a combination cell product
Study: 22079961
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of 1.25 mg bevacizumab (BCZ)
Study: 22086881
Drug: High-dose calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose calcium channel blockade as monotherapy or combination therapy
Study: 22087267
Drug: Inactivated, monovalent,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated, monovalent, non-adjuvanted pandemic (H1N1) 2009 vaccine
Study: 22087555
Drug: Treatment-as-usual at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual at inpatient family clinics
Study: 22088989
Drug: Crizotinib (dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crizotinib (dual MET/ALK inhibitor)
Study: 22090362
Drug: PD 0332991
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PD 0332991 at 125 mg once daily
Study: 22093200
Drug: Adenosine diphosphate
Normalized name: Adenosine diphosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine diphosphate (ADP) receptor inhibitors
Study: 22093206
Drug: Myeloperoxidase (MPO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myeloperoxidase (MPO) measured at arrival with a cutpoint of 210 ng/mL
Study: 22094934
Drug: Preoperative paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Preoperative paclitaxel (80 mg/m²) and gemcitabine (1,200 mg/m²) with weekly trastuzumab for 6 cycles, followed by 1 year of trastuzumab and 5 years of hormone therapy if indicated.
Study: 22094934
Drug: Preoperative paclitaxel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative paclitaxel, gemcitabine, and trastuzumab (PGH) combination therapy.
Study: 22100149
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg daily and bevacizumab 15 mg/kg every 3 weeks (Module A)
Study: 22100149
Drug: Carboplatin (AUC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (AUC = 6), paclitaxel 200 mg/m2, and bevacizumab 15 mg/kg for 4 cycles (Module B)
Study: 22100149
Drug: Maintenance erlotinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance erlotinib 150 mg daily and bevacizumab 15 mg/kg every 3 weeks (Module C)
Study: 22102646
Drug: 0.5 g/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g/kg/day intravenous undiluted alanyl-glutamine
Study: 22102709
Drug: Intensification therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensification therapy
Study: 22102709
Drug: Molecular remission
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecular remission after induction chemotherapy
Study: 22105591
Drug: Posaconazole 600-800
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole 600-800 mg/d
Study: 22105720
Drug: Oral 3-AP
Normalized name: AP
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 3-AP at 150 mg per dose
Study: 22105720
Drug: Intravenous 3-AP
Normalized name: AP
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous 3-AP at 100 mg
Study: 22105799
Drug: Anti-retinal antibody
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-retinal antibody analysis
Study: 22105894
Drug: Imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib mesylate at a dose of 400 mg/day for 1 year after surgery
Study: 22106377
Drug: Supervised, on-site
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised, on-site standard (10 h) dose of Road Tour training
Study: 22106377
Drug: Supervised, on-site
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised, on-site standard dose of Road Tour training with 4 h of subsequent booster training
Study: 22106377
Drug: Self-administered, at-home
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered, at-home standard dose of Road Tour training
Study: 22106377
Drug: Supervised, on-site
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised, on-site standard dose of attention control (crossword puzzles) training
Study: 22106730
Drug: Calcitriol ointment
Normalized name: Calcitriol Ointment
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcitriol ointment 3 microg/g applied twice daily on weekdays and clobetasol propionate spray 0.05% applied twice daily on weekends for up to 4 weeks
Study: 22109661
Drug: Real-time magnetic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Real-time magnetic resonance-guided laser-induced thermal therapy (MRgLITT)
Study: 22110166
Drug: Low-dose bacterial
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose bacterial endotoxin
Study: 22114900
Drug: Ropivacaine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 7.5 mg/ml, 20 ml infiltration
Study: 22115634
Drug: First dose
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First dose of Tdap vaccine (naïve group)
Study: 22115634
Drug: Repeat dose
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat dose of Tdap vaccine (repeat-dose group)
Study: 22115634
Drug: Repeat-dose group
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat-dose group
Study: 25418910
Drug: LVR-coil treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: LVR-coil treatment
Study: 22117586
Drug: Influenza A
Normalized name: influenza A virus
DrugBank: Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) (DB14444)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza A H1N1/09 AS03 adjuvanted vaccine (3.75 mg of haemagglutinin, two doses at 3-4 week interval)
Study: 22123298
Drug: Electrochemiluminescence (ECL)
Normalized name: 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (ECL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrochemiluminescence (ECL) assay for insulin autoantibodies (IAA)
Study: 22123298
Drug: Electrochemiluminescence (ECL)
Normalized name: 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (ECL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrochemiluminescence (ECL) assay for anti-insulin antibodies (IA)
Study: 22127697
Drug: Tumor necrosis
Normalized name: Tumor necrosis factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor necrosis factor α (TNFα) inhibitors
Study: 22127927
Drug: cediranib, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: cediranib, a pan-VEGF receptor tyrosine kinase inhibitor
Study: 22129044
Drug: Everolimus and
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus and low-dose oral cyclophosphamide
Study: 22129253
Drug: Low-dose interleukin-2
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose interleukin-2 (1.5 million IU per day for 5 days, followed by three 5-day courses of 3 million IU per day at weeks 3, 6, and 9)
Study: 22129252
Drug: Low-dose subcutaneous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose subcutaneous interleukin-2 (0.3×10(6), 1×10(6), or 3×10(6) IU per square meter of body-surface area) for 8 weeks
Study: 22133770
Drug: Subcutaneous alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous alemtuzumab 10 mg/day for 3 days and intravenous rituximab 100 mg on Days +4, +11, +18, and +25
Study: 22137491
Drug: Cancer therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cancer therapies (specifics not provided)
Study: 22137491
Drug: Alkylating agent
Normalized name: Alkylating agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alkylating agent dose score
Study: 22137491
Drug: High-dose cancer
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cancer therapy
Study: 22139909
Drug: ARRY-520 single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARRY-520 single-dose schedule (dose levels: 2.5, 3.75, 4.5, and 5.6 mg/m(2))
Study: 22139909
Drug: ARRY-520 divided-dose
Normalized name: ARRY-502
DrugBank: ARRY-502 (DB16053)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARRY-520 divided-dose schedule (dose levels: 0.8, 1.2, 1.5, and 1.8 mg/m(2)/day)
Study: 22140209
Drug: Paper prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paper prescriptions
Study: 22141572
Drug: +183 G-allele
Approvals — FDA: no, EMA: no, PMDA: no
Description: +183 G-allele
Study: 22141572
Drug: +183 G-alleles
Approvals — FDA: no, EMA: no, PMDA: no
Description: +183 G-alleles
Study: 22145984
Drug: Olaparib 100
Normalized name: olaparib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib 100 mg b.i.d.
Study: 22145984
Drug: Olaparib 200
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 200 mg b.i.d.
Study: 22145984
Drug: Olaparib 400
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 400 mg b.i.d.
Study: 22147631
Drug: Selective Serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective Serotonin Reuptake Inhibitor (SSRI) treatment for depression for 2 weeks
Study: 22147712
Drug: Nonadjuvanted H1N1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonadjuvanted H1N1 vaccine (15 mcg of hemagglutinin)
Study: 22149959
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of scAAV2/8-LP1-hFIXco
Study: 22149959
Drug: Intermediate dose
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate dose of scAAV2/8-LP1-hFIXco
Study: 22149959
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of scAAV2/8-LP1-hFIXco
Study: 22149959
Drug: scAAV2/8-LP1-hFIXco (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: scAAV2/8-LP1-hFIXco (all doses)
Study: 22152120
Drug: Neo-adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neo-adjuvant chemotherapy (EIA: etoposide 125 mg/m² iv days 1 and 4, ifosfamide 1500 mg/m² iv days 1 - 4, doxorubicin 50 mg/m² day 1, pegfilgrastim 6 mg sc day 5) followed by definitive surgery with intra-operative radiotherapy, adjuvant radiotherapy and 4 adjuvant cycles of EIA.
Study: 22152427
Drug: Sports Drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sports Drink (SPD: CHOs 68.6 g.L-1, BCAAs 4 g.L-1, caffeine 75 mg.L-1)
Study: 22153792
Drug: Infliximab 5
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 5 mg/kg intravenous infusions at weeks 0, 2, 6, 14, and 22
Study: 22154896
Drug: SODAS dexmethylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: SODAS dexmethylphenidate 20 mg
Study: 22154896
Drug: SODAS dexmethylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: SODAS dexmethylphenidate 30 mg
Study: 22154896
Drug: SODAS dexmethylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: SODAS dexmethylphenidate 40 mg
Study: 22154896
Drug: SODAS dexmethylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: SODAS dexmethylphenidate (all doses)
Study: 22155140
Drug: Etanercept (Enbrel®,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (Enbrel®, Amgen Inc.) 0.4 mg/kg/dose, subcutaneously, twice weekly, for 4 weeks (group A) or 12 weeks (group B)
Study: 22155453
Drug: Monoclonal antibody
Normalized name: Monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody 9E18 targeting GPVI dimers
Study: 22155453
Drug: ADP receptor
Normalized name: ADP-597
DrugBank: ADP-597 (DB12084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADP receptor P2Y12 antagonists
Study: 22156656
Drug: Metronomic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronomic chemotherapy regimen (vinblastine 3 mg/m2 weekly for 7 weeks, cyclophosphamide 30 mg/m2 daily for 21 days, methotrexate 10 mg/m² twice weekly for 3 weeks, celecoxib 100 mg to 400 mg twice daily for 56 days)
Study: 22156656
Drug: Metronomic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronomic chemotherapy regimen
Study: 22157574
Drug: Topical immunosuppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical immunosuppression with cyclosporine
Study: 22158386
Drug: Treosulfan (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treosulfan (3 × 14 g/m²) and Fludarabine (5 × 30 mg/m²)
Study: 22160069
Drug: Regular blood
Normalized name: Irregular blood group antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular blood transfusion therapy
Study: 22160298
Drug: Enzastaurin 500
Normalized name: Enzastaurin
DrugBank: Enzastaurin (DB06486)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzastaurin 500 mg daily and Erlotinib 150 mg daily
Study: 22160384
Drug: Anti-CD19-CAR-transduced T
Normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-CD19-CAR-transduced T cells infusion after chemotherapy and IL-2 course
Study: 22160384
Drug: Anti-CD19-CAR-transduced T
Normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-CD19-CAR-transduced T cells infusion
Study: 22165955
Drug: DAB/IL2 (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAB/IL2 (12 μg/kg; 4 daily doses; 21 day cycles)
Study: 22169779
Drug: Peg-IFN-α for
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peg-IFN-α for 9 months before and for 3 months following IM discontinuation
Study: 22169779
Drug: Peg-IFN-α therapy
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peg-IFN-α therapy
Study: 22169779
Drug: Patients off
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients off IM therapy
Study: 22170360
Drug: Red meat
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red meat intake (62.7 g per 1000 kcal in quintile 5)
Study: 22170723
Drug: Metreleptin replacement
Normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metreleptin replacement therapy (0.08 mg/kg·d by twice daily sc injections for 6 months) in SH group
Study: 22170723
Drug: Metreleptin replacement
Normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metreleptin replacement therapy (0.08 mg/kg·d by twice daily sc injections for 6 months) in MH group
Study: 22170723
Drug: Metreleptin replacement
Normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metreleptin replacement therapy in SH group
Study: 22170723
Drug: Metreleptin replacement
Normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metreleptin replacement therapy in MH group
Study: 22171692
Drug: Metformin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin treatment (in both sets)
Study: 22171697
Drug: Neoadjuvant chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemoradiation therapy (25 fractions of 2 Gy with concurrent capecitabine) followed by Transanal Endoscopic Microsurgery (TEM)
Study: 22172590
Drug: 8-h nocturnal
Normalized name: Nocdurna
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 8-h nocturnal in-center thrice weekly hemodialysis (NHD)
Study: 22172590
Drug: 4-h thrice
Normalized name: Thrive 4 MG Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-h thrice weekly conventional hemodialysis (CHD)
Study: 22173060
Drug: Rituximab (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (375 mg/m² intravenously once a week for 4 weeks) followed by CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone every 3 weeks for 4 cycles)
Study: 22176583
Drug: Sit-to-stand activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sit-to-stand activity prompted by health care aides (twice daily during care routines)
Study: 22176869
Drug: Sunitinib 37.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 37.5mg once daily continuously with 4-week cycle
Study: 22177085
Drug: High cereal-fiber
Approvals — FDA: no, EMA: no, PMDA: no
Description: High cereal-fiber diet (HCF, 43 g/day)
Study: 22177085
Drug: High-protein diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein diet (HP, 28% of energy-intake, cereal-fiber 14 g/day)
Study: 22177085
Drug: Moderately high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately high cereal fiber/protein diet (MIX, protein 23% of energy-intake, cereal-fiber 26 g/day)
Study: 22177085
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (cereal-fiber 14 g/day)
Study: 22178121
Drug: Bevacizumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (15 mg/kg) and cisplatin (100 mg/m(2)) on days 1, 22, and 43 of radiation (70 Gy) with intensity-modulated radiation therapy over 33 days, followed by bevacizumab (15 mg/kg) and cisplatin (80 mg/m(2)) on days 64, 85, and 106 after radiation, and fluorouracil (1000 mg/m(2) per day) on days 64-67, 85-88, and 106-109 after radiation.
Study: 22179536
Drug: Collagenase therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagenase therapy (300 to 1200 μg) delivered locally into occlusions via over-the-wire balloon system or fine-cross microcatheter for 30 minutes.
Study: 22179536
Drug: Collagenase therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagenase therapy (300 to 1200 μg) delivered locally into occlusions.
Study: 22180427
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of deferiprone and desferrioxamine
Study: 22182397
Drug: NGX-4010 (capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: NGX-4010 (capsaicin 8% dermal patch) after pretreatment with lidocaine 2.5%/prilocaine 2.5% cream
Study: 22182397
Drug: NGX-4010 (capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: NGX-4010 (capsaicin 8% dermal patch)
Study: 22185672
Drug: Artemether-lumefantrine (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-lumefantrine (standard treatment)
Study: 22185681
Drug: Epidural injection
Normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injection of 80 mg acetate methylprednisolone
Study: 22185681
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of 80 mg acetate methylprednisolone
Study: 22185733
Drug: Decongestion (0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decongestion (0.05% oxymetazoline chloride applied as an aerosol spray)
Study: 22186627
Drug: Bortezomib (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib (1.5 mg/m2) administered twice a week for 2 consecutive weeks (days 1, 4, 8, and 11) followed by a 10-day rest period.
Study: 22186627
Drug: Bortezomib (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib (1.5 mg/m2) administered as described above.
Study: 22189340
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g ertapenem
Study: 22190606
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of etravirine/12 h (Control)
Study: 22190606
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of etravirine/24 h (Intervention)